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A B S T R A C T
More than a million women are diagnosed with breast cancer annually worldwide. Death from breast cancer is usually a result of 
chemotherapy-resistant metastatic disease. Eribulin mesylate is a recent addition to the therapeutic armamentarium for treating 
locally advanced or metastatic breast cancer (MBC) in patients who have received at least two prior chemotherapy regimens for 
late-stage disease. This synthetic analog, derived from a marine sponge macrolide halichondrin B, inhibits microtubule stability 
by blocking microtubule growth without affecting microtubule shortening. The US Food and Drug Administration has approved 
eribulin mesylate as a third-line treatment for MBC refractory to anthracyclines and taxanes based on a Phase III clinical trial 
showing significantly increased overall survival compared to treatment of investigator’s. Asthenia, fatigue, neutropenia, alopecia, 
nausea, anorexia, and neuropathy are the most frequent adverse effects associated with this drug. The aim of this review was 
to highlight the importance of this drug in the management of breast cancer. Medline, Excerpta Medica database, cochrane 
database, medscape, Elsevier Scopus, and clinicaltrials.gov were searched using terms “eribulin,” “E7389,” “halichondrin,” 
“metastatic breast cancer.” Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were 
screened. The development of this microtubule inhibitor helps to address the need for additional effective regimens for patients 
progressing after standard treatment with anthracycline- and taxane-containing regimens.
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Breast cancer is the most common cancer in females 
worldwide accounting for 23% of all newly occurring 
cancers.[1] Breast cancer is the most common cause of 
cancer-related death among women in the USA.[2] In India, 
breast cancer ranks as the second most common cancer 
except in metropolitan cities where its incidence is higher 
than cervical cancer.[3] In addition, breast cancer accounts 
for the second most common (1.7%) cause of cancer-related 
deaths.[3]
Breast cancers have been grouped into four distinct 
molecular subtypes based on gene expression profiling: 
Luminal A, Luminal B, basal-like and human epidermal growth 
factor-2 (HER2) tyrosine kinase positive.[4] HER2-positive 
subtype is a particularly aggressive clinical phenotype shown 
by approximately 20-30% patients and characterized by 
amplification or overexpression of the HER2 gene; patients 
of this subset generally benefit from anti-HER2-targeted 
therapy.[5] Triple negative breast cancer (TNBC) is another 
aggressive phenotype with a poor prognosis, classified as 
basal and defined as disease negative for HER2 as well as 
for estrogen and progesterone. About one-third cases have 
a central nervous system (CNS) metastasis.[6,7] There remains 
an urgent unmet need for improved targeted agents for this 
patient population.[8]
Multiple factors delay the diagnosis in Indian women, such 
as limited availability and access to cancer health services, 
lower health literacy, and a social stigma attached to breast 
cancer. The increasing burden of disease is associated with 
lifestyle factors such as late age at marriage, age at first 
birth, reduced breast feeding, westernization of diet, and 
physical activity patterns.[1]
Though only 5% of patients have overt metastatic disease 
at diagnosis, but at least 30% of those initially diagnosed 
with early breast cancer will later relapse.[9] Despite 
significant advances, metastatic breast cancer (MBC) is still 
considered an incurable disease, with a median survival of 
2-3 years; it varies according to histological and molecular 
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subtype and age of patient. The most common sites of 
distant metastasis are lungs, liver, lymph nodes, and bone. 
Low-risk group includes patients who develop metastatic 
disease after a long disease-free interval, those whose 
tumors are positive for a hormone receptor (estrogen or 
progesterone), those with bone-only disease, and those 
without extensive visceral organ involvement. High-risk 
patients include those with rapidly progressive disease or 
visceral involvement and those with disease shown to be 
refractory to hormonal manipulation. Factors that predict 
early recurrences (within 2-3 years of diagnosis) include 
advanced stage of the primary tumor, younger age, poorly 
differentiated histology, negative hormonal receptors, 
ErbB2 receptors and urokinase plasminogen activator 
overexpression, and the type of treatment modality used 
at the time of initial diagnosis; HER2, TN, and luminal B 
subtypes relapse earlier.
Stage IV breast cancer comprising of locally advanced breast 
cancer (LABC) or MBC is a major therapeutic challenge. 
Factors that help decide the choice of therapy include longer 
versus shorter disease-free interval, age, menopausal status, 
site(s) of recurrence (soft-tissue and bone vs. visceral), 
the bulk of recurrent disease, symptomatic disease or 
not, prior adjuvant therapy, organ functions, performance 
status, co-morbidities, as well as tumor characteristics such 
as hormone responsiveness status and ErbB2/HER 2-neu 
receptor expression.[10]
The current standard strategy to predict hormone 
sensitivity is the detection of estrogen receptor (ER) 
and/or progesterone receptor, which are present in 
Luminal A and Luminal B breast cancer. Endocrine therapy 
is recommended as primary systemic therapy for patients 
with MBC and positive hormone receptors. Endocrine 
manipulations used in treatment of post-menopausal MBC 
as well as in pre-menopausal women with non-visceral, 
bone disease as well as low-bulk visceral MBC are selective 
estrogenic receptor modulators, aromatase inhibitors, and 
progestational agents. The first-line hormonal therapy 
consists of an aromatase inhibitor or tamoxifen. Second-line 
agents include fulvestrant, a selective estrogenic receptor 
down regulator and luteinizing hormone releasing hormone 
agonists.
The choice of therapy for patients with MBC typically 
depends on the risks and benefits of each treatment 
option, the disease burden and subtype, prior therapeutic 
exposure, availability, and the patient and physician 
preference.[5,11] Initiation of systemic chemotherapy is 
appropriate for women with metastatic disease that is 
either hormone receptor-negative, refractory to endocrine 
therapy, or rapidly progressive, with important visceral 
involvement regardless of hormonal status. Current 
chemotherapeutic options for treatment of MBC include 
taxanes, anthracyclines, vinca alkaloids, gemcitabine, 
capecitabine, ixabepilone, and newer formulations of 
old drugs such as cationic liposomal anthracyclines and 
nanoparticle-albumin-bound paclitaxel. Taxanes have 
serious dose-limiting toxicities such as myelosuppression, 
peripheral sensory neuropathy, allergic reactions, and 
eventual development of drug resistance.[12] A recent trial 
comparing docetaxel with vinorelbine in anthracycline 
pre-treated disease showed lower response rates with 
vinorelbine as compared to docetaxel, though hematological 
adverse effects were ten-fold greater with docetaxel.[13] Most 
of these chemotherapeutic agents have not demonstrated 
an impact on survival in patients.[14] A recent trial showed 
that ixabepilone plus capecitabine significantly improves 
progression-free survival (PFS) compared with capecitabine 
alone in anthracycline-, taxane-pre-treated, or resistant 
patients.[11] Use of chemotherapy can give up to 50-70% 
response rates when used in combination, but it can also 
produce more toxicity. Sequential administration of taxanes 
and anthracyclines is preferred except in aggressive, bulky 
visceral involvement, especially in young patients. Though 
debate continues over combination chemotherapy versus 
sequential mono-therapy, a recent survey of 152 practicing 
nationwide oncologists revealed preference for use of 
platinum agents and oral agents (such as capecitabine), 
despite the lack of evidence from large randomized trials.[15] 
The exact total duration of therapy depends on the response 
and toxicity profile of the drugs used.
Recent advances in the therapeutic armamentarium 
against MBC include anti-ErbB2 therapy, exemplified by 
trastuzumab, pertuzumab, and neratinib. Trastuzumab has 
shown prolonged overall survival (OS) as first-line therapy 
for MBC. Though cardiac toxicity prevents its concurrent 
use with anthracyclines, it can be safely given with 
vinorelbine or taxanes. Lapatinib is a reversible dual tyrosine 
kinase inhibitor that is active in trastuzumab-resistant 
ErbB2-positive cells. T-DM1 is an antibody–drug conjugate. 
The antibody is trastuzumab; DM-1 (emtansine) is 
an anti-tubule agent. Other drugs in pipeline include 
HER-affitoxin, anti-DNA repair therapy, anti-angiogenic 
therapy, and poly (adenosine diphosphate ribose) 
polymerase-1 (PARP-1) inhibitors. Advances in treatment 
of MBC are being rapidly moved to the neoadjuvant and 
adjuvant settings where eradicating micrometastasis is 
producing better survival and more cures.[10]
Microtubule inhibitors are among the most frequently 
used agents for breast cancer chemotherapy, with proven 
efficacy in both localized and metastatic disease.[16] 
Current microtubule-targeted treatment is often limited 
by development of primary or acquired drug resistance 
and common side-effects of chronic peripheral sensory and 
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motor neuropathy that have driven the quest for agents that 
could be used in taxane-resistant disease or replace taxanes 
in the early stages of treatment.[17] Recognized mechanisms 
of resistance include altered expression of the adenosine 
triphosphate-binding cassette superfamily of transporters, 
alteration in DNA repair pathways, mutations in cellular 
targets, resistance to initiation of the apoptotic pathway, 
and the development of constitutively activated signaling 
pathways. The combined use of agents that intersect 
in receptor crosstalk, such as between the ER and the 
mammalian target of rapamycin have demonstrated synergy 
in anti-tumor effects. The recent report of exemestane used 
in combination with everolimus has shown great promise in 
this regard.[18]
Eribulin mesylate is a synthetic analog of halichondrin B, a 
large polyether macrolide and is a natural product isolated 
from the marine sponge Halichondria okadai. Scarcity of 
the natural product once hampered efforts to develop 
halichondrin B as an anti-cancer drug, but a synthetic and 
structurally simplified derivative with retained high potency 
and the biologically active macrocyclic lactone C1-C38 
moiety of the parent compound was developed.[19]
METHODS OF LITERATURE SEARCH
Medline, Excerpta Medica database (EMBASE), cochrane 
database, medscape, Scopus database, and clinicaltrials.
gov were searched for published studies using the terms 
“eribulin,” “E7389,” “halichondrin B,” and “metastatic breast 
cancer.” Journal articles published in English language from 
2007 to 2012 discussing pharmacology and/or clinical trials 
of eribulin were screened.
PHARMACOKINETICS
Eribulin is prepared as an aqueous solution with no 
requirement of a solvent. It shows linear pharmacokinetics, 
with rapid distribution, slow elimination, and low renal 
excretion of unchanged drug. Eribulin has a mean half-life 
of 40 h, rapid and extensive volume of distribution, and 
slow-to-moderate clearance. Though metabolized by 
cytochrome P450 (CYP3A4), it does not affect the metabolism 
of other therapeutic agents. The recommended dose of 
eribulin is 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin 
mesylate) to be administered intravenously over 2-5 min 
on days 1 and 8 of a 3-week cycle.[20] Eribulin, which is 
prepared in an aqueous solution, has a short infusion 
time, can be administered with or without dilution, does 
not require steroid or anti-histamine pre-medications, and 
protection from light is not necessary. These are the distinct 
advantages of eribulin as compared to currently approved 
microtubule-targeting agents.[21] The recommended 
dose of eribulin in normal, mild hepatic (Child Pugh A), 
moderate hepatic (Child Pugh B), and moderate renal 
impairment (creatinine clearance 30-50 mL/min) is 1.4, 1.1, 
0.7, and 1.1 mg/m2, respectively, as a 2-5 min intravenous 
bolus on days 1 and 8 of 21-day cycle.[21]
MECHANISM OF ACTION
Microtubules are a core component of the mitotic spindle that 
separates chromosomes during eukaryotic cell division.[22] 
Microtubule-targeted agents such as taxanes (paclitaxel 
and docetaxel), vinca alkaloids (vinorelbine and 
vinblastine), and epothilones (ixabepilone) act by 
inhibiting microtubule dynamics, thereby promoting 
cell cycle arrest and apoptosis.[22,23] Eribulin possesses 
a unique chemical structure compared with approved 
tubulin-targeted agents [Figure 1]. The novel mechanism 
of action of eribulin, distinct from other known classes 
of tubulin-targeted agents involves suppression of 
microtubule polymerization without affecting microtubule 
depolymerization. In contrast to taxanes and vinca 
alkaloids which suppress both the growth and shortening 
phase of microtubule dynamic instability, eribulin binds to 
interdimer interface or β-tubulin subunit alone and inhibits 
only the microtubular growth phase of microtubular 
dynamics instability in interphase cells (polymerization) 
with no effect on shortening (depolymerization).[24,25] 
Eribulin also promotes centromere spindle relaxation 
without affecting the rate of stretching.[9] Tubulin is 
sequestered into non-functional aggregates, leading to 
an irreversible arrest at G2-M phase followed by apoptosis 
after prolonged mitotic blockade.[26-28] Several biochemical 
correlates of apoptosis are seen in eribulin-treated 
human lymphoma and prostate cancer cells, including 
phosphorylation of Bcl-2, cytochrome c release from 
mitochondria, activation of caspase-3 and -9, and cleavage 
of PARP.[19]
Figure 1: Eribulin mesylate
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CLINICAL STUDIES WITH ERIBULIN 
MESYLATE
Eribulin has demonstrated broad spectrum pre-clinical 
anti-tumor activity against a wide variety of human cancer 
types.[29] Encouraging Phase I and Phase II studies paved 
the way for the Phase III trial EMBRACE (Eisai MBC study 
Assessing Physicians choice vs. E7389).[30] 762 women 
with LABC or MBC were randomly allotted in a 2:1 ratio to 
eribulin 1.4 mg/m2 over 2-5 min on days 1 and 8 of a 21-day 
cycle (n=508) or treatment of physicians choice (TPC) (n=254), 
defined as any single-agent chemotherapy or hormonal, 
or biological treatment approved for the treatment of 
cancer and to be administered according to local practice, 
radiotherapy, or symptomatic treatment alone.[31] The TPC 
arm was selected because at that time, there was no single 
internationally acceptable or approved chemotherapy 
regimen for women with heavily pre-treated MBC. This 
design had the added advantage of reflecting “real life” 
choices for these women. Treatment continued until 
disease progression, unacceptable toxic effects, patient 
or physician request to discontinue, or serious protocol 
non-compliance. The study results showed a significant 
increase in OS for eribulin (13.1 months, 95% confidence 
interval (CI): 11.8-14.3) compared with TPC (10.6 months, 
95% CI: 9.3-12.5; hazard ratio (HR): 0.81, 95% CI: 0.66-0.99; 
P=0.041) in the intention-to-treat population. The median 
PFS in eribulin-treated and TPC groups was 3.7 months 
(95% CI: 3.3-3.9) and 2.2 months (2.1-3.4), respectively (HR: 
0.87, 95% CI: 0.71-1.05; P=0.137).[32] The study highlighted 
that improvement in OS is an achievable endpoint in the 
advanced breast cancer setting.[33]
In a recent Phase III trial that compared eribulin with 
capecitabine involving 1102 patients, eribulin showed 
anti-cancer activity early in the course of MBC. Although 
not statistically significant, eribulin in comparison with 
capecitabine demonstrated an OS benefit (15.9 vs. 
14.5 months (HR: 0.879; 95% CI: 0.770-1.003; P=0.056)). 
Further evaluations of patient subsets showed greater 
median OS in HER2-negative breast cancer (15.9 vs. 
13.5 months (HR: 0.838; 95% CI: 0.715-0.983; P=0.030)) and 
TNBC patients (14.4 vs. 9.4 months).[34,35]
Preliminary results from a Phase II study of eribulin with 
trastuzumab as first-line therapy for HER2  +  LABC/MBC 
showed an objective response rate (ORR) of 59.3% and 
median PFS of 9.2 months (range: 1.35-14.19 months). The 
combination showed considerable activity with acceptable 
toxicity to warrant further exploration.[36]
In a single-arm, multi-center open-label Phase II trial, 
Japanese patients pre-treated with an anthracycline and a 
taxane received 1.4 mg/m2 eribulin mesylate; ORR observed 
was 21.3% (95% CI: 12.9-31.8), PFS was 3.7 months (95% CI: 
2.0-4.4), and OS was 11.1 months (95% CI: 7.9-15.8).[37]
A Phase II study is evaluating the toxicity profiles of 
combination of eribulin and cyclophosphamide versus 
docetaxel/cyclophosphamide as neoadjuvant therapy for 
locally advanced HER2-negative breast cancer. Another 
Phase II trial will study how well the co-administration of 
eribulin mesylate and carboplatin together before surgery 
works in treating patients with stage I-III TNBC. Ongoing 
trials are investigating the role of eribulin (mono-therapy 
and combination) as first-line therapy for MBC and 
also along with targeted agents such as lapatinib and 
ramucirumab. A study evaluating important quality of life 
and pharmacokinetic correlates is currently recruiting 
participants. Eribulin is also being evaluated in advanced or 
recurrent cervical cancer.[38]
Though eribulin has been evaluated in Phase II studies in 
other advanced solid carcinomas, such as non-small-cell 
lung carcinoma, pancreatic carcinoma, and head and neck 
tumors, it did not result in clinically significant median PFS 
in these tumors.[39-42] However, in a recent Phase II study, 
eribulin mesylate demonstrated activity and a relatively 
favorable toxicity profile in patients with metastatic 
castration-resistant prostate cancer.[43]
ADVERSE EFFECTS
Eribulin has demonstrated a manageable tolerability 
profile. In the EMBRACE study, direct comparison of 
individual toxicity between eribulin and TPC is complicated 
by the heterogenous nature of the TPC treatments and their 
differing side-effect profiles. The most common adverse 
effects observed in both the treatment arms were asthenia 
(or fatigue) and neutropenia, most of which were Grade 1 
or 2.[44,45] Grade 3 or 4 events that were more frequent in 
the eribulin group than in the TPC group were leukopenia, 
neutropenia, and peripheral neuropathy. There was more 
myelosuppression with eribulin, incidence of Grade 3 or 4 
neutropenia being 45% versus 21%; majority of these were 
asymptomatic. Nevertheless, the incidences of Grade 3 and 
4 febrile neutropenia and peripheral neuropathy were low.
Peripheral neuropathy was the most common adverse event 
leading to discontinuation of eribulin in 5% of patients, but in 
those patients with Grade 3 or 4 peripheral neuropathy who 
discontinued treatment, neuropathy improved to Grade 2 
or lower in later cycles after delays and dose reductions.[46] 
An experimental study by Wozniak et al. indicated that 
eribulin mesylate induces less neuropathy in mice than 
paclitaxel or ixabepilone at equivalent maximum tolerated 
dose-based doses.[47]
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Clinically also, eribulin has shown a lower incidence 
of severe neuropathy as compared to ixabepilone and 
paclitaxel. In a Phase II study, incidences of peripheral 
neuropathy and treatment-emergent neuropathy eribulin 
versus ixabepilone were 31.3% versus 44.0% (P=0.16) and 
33.3% versus 48.0% (P=0.13). Eribulin showed a longer time 
to onset of treatment-emergent neuropathy and fewer 
discontinuations due to neuropathy and other toxicities.[48]
CURRENT PLACE IN THERAPY
The Food and Drug Administration (FDA) has approved 
three agents for treatment of patients with MBC refractory 
to anthracyclines and taxanes: Capecitabine, ixabepilone, 
and eribulin mesylate.[49] As MBC is no longer curable, 
primary goals of therapy in this setting and particularly in 
later lines of therapy include improving/maintaining quality 
of life, reducing tumor-related symptoms, and prolonging 
survival. However, there is no fixed algorithm of therapeutic 
choices.[50]
Eribulin is a promising new alternative for women with 
pre-treated (including an anthracycline and a taxane) MBC. It 
is the third single-agent chemotherapy that has improved OS 
(after anthracycline and taxane) in advanced breast cancer.[51] 
The US FDA has approved eribulin mesylate as a third-line 
for MBC refractory to anthracyclines and taxanes. Its unique 
mechanism of action enhances its ability to overcome 
chemo-resistance. Eribulin has shown clinical activity in 
patients with a wide range of tumors who had exhausted 
established treatment options.[9,52] Many tubulin-targeted 
agents have the disadvantage of long infusion times. The 
infusion time for eribulin is significantly shorter than 
other intravenously administered microtubule-targeted 
agents (less than 5 min vs. 180 min).[53] Unlike current 
agents that need to administer pre-medications, and special 
storage, mixing, or administration requirements, eribulin 
does not need any such preparations.[54] In a cost-analysis 
study based on clinical data from the EMBRACE trial, eribulin 
added 0.208 life-years saved and 0.119 quality-adjusted life 
years (QALY) with an incremental cost over TPC of $24,035; 
and therefore, a cost of $115,369/LY and an incremental 
cost-effectiveness ratio of $201,790/QALY. Eribulin was 
shown to be cost-effective when compared to doxorubicin, 
nab-paclitaxel, ixabepilone, and capecitabine but showed 
marginal cost-effectiveness for less expensive drugs such as 
vinorelbine and gemcitabine.[55,56]
A manageable side-effect profile, a low incidence of 
peripheral neuropathy, tolerance at full doses in renal 
dysfunction, and lack of drug–drug interactions or 
hypersensitivity make eribulin a welcome addition to 
the therapeutic armamentarium against advanced breast 
cancer. Novel amine-containing analogs of eribulin 
mesylate are being designed and have shown efficacy 
in multidrug resistant (MDR) tumors.[57] Since eribulin is 
the only drug that has shown a survival advantage, it is 
likely to be partnered with other chemotherapy agents, 
anti-HER2 agents, and other drugs targeting important 
biologic pathways. Ultimately, identification of predictors 
of response will be critical for rational patient selection and 
for limiting non-specific toxicities in those who are unlikely 
to benefit. The identification of biomarkers to predict 
therapeutic response to eribulin will greatly enhance its 
use in the breast cancer treatment armamentarium.[19] 
Nevertheless, eribulin establishes a potential new standard 
treatment for women with heavily pre-treated MBC, for 
whom there was no chemotherapy treatment with proven 
survival benefit till now.
CONCLUSION
Breast cancer is the most common cancer in women through 
the 21st century. Management of advanced breast cancer 
depends on the site and extent of metastases, co-morbid 
conditions, and clinical tumor characteristics. Resistance 
to chemotherapeutic agents remains a consistent obstacle 
in treatment success. Eribulin is a non-taxane microtubule 
dynamics inhibitor, approved by the FDA for use in 
patients who have previously received at least two prior 
chemotherapeutic regimens for MBC. The low probability 
of drug–drug interactions, easy administration as bolus, 
low hypersensitivity chances, and good tolerability in renal 
dysfunction patients make eribulin a promising drug. This 
novel spindle toxin presents clinicians with a beneficial 
addition to the therapeutic arsenal.
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